Targeted Strategies for Today's Evolving Markets

MissionIR Blog

International Stem Cell Corp. (ISCO) Eyes Growth through Partnerships to Develop Therapeutic and Biomedical Products Worldwide

International Stem Cell Corp. (OTCQB: ISCO) builds shareholder value through the development of restorative medicine using stem cell technology. Through its innovative parthenogenesis technology, the company makes use of human stem cells from unfertilized oocytes (eggs), bypassing common ethical controversy that accompanies the destruction of the viable human embryo. Additionally, the company works with subsidiaries Lifeline Skin Technology and Lifeline Skin Care in the area of skin rejuvenation on a product that contains a nano-compound that facilitates the replenishment of the skin’s texture and elasticity.

Evidence of the company’s resolve to be a leader in the field of restorative medicine can be found in a recent partnership with The Florey Institute of Neuroscience and Mental Health, one of the world’s leading brain research centers. The agreement calls for the team to launch Phase I/IIa clinical trials research on the effects of human parthenogenetic stem cells in people with Parkinson’s disease.

The credibility The Florey Institute brings to ISCO’s mission to build shareholder value cannot be understated. The Florey Institute of Neuroscience and Mental Health is one of the world’s leading brain research centers, employing a staff of over 500. The center’s scientists comprise the largest neuroscience research team in Australia. Its work is conducted on a range of serious diseases, including stroke, epilepsy, Alzheimer’s disease, Parkinson’s disease, traumatic brain and spinal cord injury, depression, multiple sclerosis, Huntington’s disease, motor neuron disease, schizophrenia, mental illness and addiction. Further, The Florey is viewed by many as a world leader in imaging technology, stroke rehabilitation and epidemiological studies.

The company’s human cell culture products are made up of adult stem cells and reagents for regenerative medicine aiding in the study of prostate disease, human renal and bladder diseases, human corneal cells present in corneal disease and other cell culture reagents and supplements for the growth, staining, and freezing of human cells. ISCO markets and sells skincare products through its website, channel sales, distributors and human cell culture products through its sales force, OEM partners, and brand distributors. International Stem Cell Corp. was founded in 2001 and is headquartered in Carlsbad, California.

For more information, visit

Posted in International Stem Cell Corp. ISCO | Leave a comment

Torchlight Energy Resources, Inc. (TRCH) Moving Forward with Planning of Next Phase of Drilling on Orogrande Project

Earlier today, Torchlight Energy Resources, Inc. (NASDAQ: TRCH) announced that the Orogrande Development Committee, which consists of members of the project operator, Torchlight and consulting geologist Rich Masterson, has elected to move forward on planning the next phase of drilling in the Orogrande Project. Following this decision, the project operator is expected to permit three new wells, beginning with the University Founders B-19 #1 well, to be drilled vertically for test purposes. These new wells will be designed with sufficient casing size to support lateral entry into any pay zones encountered during testing – including pay zones previously observed in the existing Cactus well.

“We are pleased that the project operator is underway on next steps in evaluating our Orogrande Project,” Will McAndrew III, chief operating officer of Torchlight, stated in the news release. “Drilling additional test wells is the appropriate next action, providing data necessary for validation of the play and the development plan for the entire 168,000 acres. Our principal strategy is to create control data by strategically placing wells across the acreage and thus creating a development thesis for the entire basin.”

Field operations stemming from this agreement are set to begin within 90 days and in line with the development agreement. Last September, Torchlight announced entry into a definitive agreement with Founders Oil and Gas, LLC of Midland, Texas, through which Founders will contribute $50 million in development capital by 2017 – including a $5 million reimbursement for initial project costs – in exchange for 50 percent working interest in the Orogrande Project. Following the commencement of new drilling operations, Torchlight will receive a payment of $500,000 resulting from this partnership.

“The capital and expertise being provided by our operating partner has set the stage for continued value creation for Torchlight and our shareholders,” concluded McAndrew.

Currently, Torchlight owns 95 percent working interest in the 168,000 acre Orogrande Project, which is located in Hudspeth County, Texas. The company is targeting 1,300 feet of pay at a depth of approximately 4,000 to 6,100 feet. In prior testing, Torchlight utilized the Rich A-11 well to gather key data for its field development thesis, but a poor cement bond discovered during testing prevented a cost-effective production test of the project’s primary pay zones. Repairing these defects was determined to be economically unfeasible, and, as a result, the development committee approved plans for drilling of the next wells with larger casings that can be utilized for both testing and commercial production moving forward.

For more information on the company, visit

Posted in Torchlight Energy Resources, Inc. TRCH | Leave a comment

OurPet’s Company’s (OPCO) Partnership with Aplix will Catalyze New Innovations in the Pet Tech Space

The recent announcement by OurPet’s Company (OTCQX: OPCO) of a new strategic partnership with the Japanese software developer, Aplix IP Holdings Corp., shows that the Fairport Harbor, Ohio, company is exploring new frontiers in the pet technology market. Just as new digital technologies have expanded and are continuing to expand our capabilities, they are opening up new possibilities for our pets.

There are existing pet tech devices on the market currently, allowing you to stay in complete contact with your pets. One of the most basic pet tech devices is, of course, a GPS tracker. A tracker can substantially reduce the amount of time you spend in a state of anxious insecurity regarding your pet’s whereabouts. Then, if you want to see where your dog goes (and who doesn’t?) there’s a company that makes a harness fitted with a camera. As pet-parents become more comfortable with new technologies for themselves, it’s apparent they will want to extend their application to the pet members of the family.

Social media is not only for pet-parents. You may have your Facebook (NASDAQ: FB) account. Your dog can have a homepage on Pack. Pack allows you or your dog, it’s not clear which, to ‘connect with your pack’. If you have a Twitter (NYSE: TWTR) account, why don’t you get one for your canine? Puppy Tweets is an electronic dog tag that sends messages to your home computer, and then Tweets to you. Welcome to a brave new world!

The technology that may help OurPet’s Company get a paw-hold in these lucrative markets may be the WirelessIDEA platform. Aplix IP Holdings Corp. showcased its WirelessIDEA software-based technology for machine to machine (M2M) applications at the International CTIA Wireless IT & Entertainment trade show in San Diego back in October 2009. WirelessIDEA provides tools that enable rapid development of M2M applications. Aplix is well-known for its JBlend, a Java Micro Edition (Java ME) platform for embedded software, which has been installed in close to three-quarters of a billion devices worldwide.

This sort of innovation is nothing new to OurPet’s Company. The company has a history of developing bright ideas. Its first was the introduction of the Big Dog Feeder, which made it easier for big dogs to eat by elevating the feeding bowl – low tech, but effective. The Big Dog Feeder has, over the years, enjoyed great success, but OurPet’s Company isn’t the sort of outfit to rest on its laurels. Its founder is an enterprising dynamic engineer who has been elected to the National Inventors Hall of Fame. Today, the company actually sells more toys for pets than feeding products. In recent years, OurPet’s Company has been growing at twice the rate of the industry. Since 2010, it has had an annual compounded growth rate of about 6%. That seems very likely to increase as OurPet’s Company gears up in pet tech.

For more information, visit the company’s website at

Posted in OurPet’s Company OPCO | Leave a comment

Oakridge Global Energy Solutions, Inc. (OGES): Lithium-ion Batteries ‘Made in the USA’

The global market for lithium ion batteries is a fast growing one and is expected to cross $30 billion by 2020. It continues to advance as high power and high capacity cells increase penetration into large-format applications. Vying for market adoption, the lithium-ion chemistry competes heavily with established energy storage technologies, such as lead acid, in many of these applications. However, key performance characteristics have enabled lithium-ion to increase market penetration, resulting in growth opportunities. Oakridge Global Energy Solutions, Inc. (OTCQB: OGES) has two production facilities in Melbourne, Florida, making high quality lithium-ion batteries with the ‘Made in the USA’ label.

Lithium-ion batteries are most commonly used in small consumer devices like smartphones and laptops. However, more recently, lithium-ion technology is being used in electric vehicles and storage applications. The electric car market is growing rapidly and, after visiting a local Tesla Motors, Inc. (NASDAQ: TSLA) dealership, the reasons are obvious. Someone can buy an electric car with 762 horsepower, drive it for 300 miles, recharge it from any common outlet or charge station for free, and continue on their cross-country trek. When buying an electric car, the purchaser receives a substantial tax credit and doesn’t have any maintenance issues – like an oil change or tire rotation – for 50,000 miles.

Oakridge Global is in position to benefit from this growing trend. Its innovative ‘Made in the USA’ product line includes multiple lithium-ion technologies and form factors that are optimized to address three high-demand target markets – including stationary and grid storage; motive applications, such as electric and hybrid electric fleet vehicles; and specialty applications, such as military, aerospace, marine, medical and telecom backup.

It’s only a matter of time before people begin calculating their yearly gas bill and compare it to the more efficient, environmentally friendly electric vehicle option. Charge stations are multiplying rapidly and many hotels are jumping on board by adding them to locations across the country. Oakridge Global offers a high quality product with domestic roots and, more importantly, domestic jobs. ‘Made in the USA’ is beginning to mean something again, and people are taking this into consideration when shopping for big purchase items such as cars, motorcycles, boats, RV’s, etc.

For more information, visit

Posted in Oakridge Global Energy Solutions Inc. OGES | Leave a comment

Moxian’s (MOXC) Marketing Magic Casts a Spell on Youtube and Youku

Moxian, Inc (OTCQB: MOXC) is reaching a new generation of shoppers and merchants with its exciting promotional videos on YouTube and Youku. YouTube, according to Alexa Internet, which analyzes web traffic, is currently the world’s third most visited site, and stats published by YouTube itself claim the site has ‘over a billion users – almost a third of all people on the Internet – and every day, people watch hundreds of millions of hours of YouTube videos and generate billions of views.’ It’s certainly a good place to be, particularly if you’re targeting the young and the restless. Again according to YouTube, ‘YouTube overall, and even YouTube on mobile alone, reaches more 18 – 34 and 18 – 49 year-olds than any cable network in the U.S.’

YouTube viewership is important for Moxian (pronounced MO-SHUN), even though the company’s main area of operations is in mainland China. The population of the Chinese diaspora is huge. An Economist piece ( of 2011 divulged that ‘More Chinese people live outside mainland China than French people live in France, with some to be found in almost every country.’ At that time, the population of France was about 65 million (It’s about 67 million now). Most of these overseas Chinese live, of course, in Asia. Thailand has over 9 million; Malaysia almost 7 million; Indonesia 2.8 million; and Myanmar, about 1.6 million. However, significant numbers live elsewhere and in the Americas. Peru and Canada each have roughly 1.3 million and 3.46 million persons who identify as Chinese live in the U.S.

Of course, YouTube is not accessible from China and hasn’t been since 2009, according to a CNN story ( On Monday, March 23rd of that year, Google reported ‘it began noticing a decline in traffic from China about noon. By early Wednesday, site users inside China continued to encounter an error message: “Network Timeout. The server at is taking too long to respond.”

Moxian’s initial forays have taken it to mainland China. The Moxian platform was first offered in beta version in Shenzhen, a major city of over 10 million, noted for being ‘China’s first and one of the most successful Special Economic Zones (SEZ).’ In China, Youku takes the place of Youtube. Back in 2010, Youku’s CEO Victor Koo told Bloomberg, ‘he’s tired of being asked whether his company, China’s biggest online-video provider, is the nation’s version of YouTube or Hulu’. He replied, “It’s both and better.” A PRNewswire Press Release ( from Youku stated, ‘Youku Tudou Inc. (NYSE: YOKU) is China’s leading Internet television company. Its Youku and Tudou Internet television platforms enable users to search, view and share high-quality video content quickly and easily across multiple devices. Its Youku brand and Tudou brand are among the most recognized online video brands in China.’

The Moxian videos on Youku are narrated by cartoon characters, which are favored in Asia. Moxian cleverly capitalizes on the admiration that the Chinese have for Americans and Europeans by marketing its platform in China as Spellthread. The Spellthread domain was acquired by the company under an Intangible Asset Transfer Agreement with Fensheng Kuan, which gave it the right to use as well, according to an 8-K filing by the company in 2013.

One of the Youku Spellthread videos tells how the Spellthread+ App has ushered in the ‘no card payment era’ and gives details on how the hassle of making payments and carrying out transactions in China can be avoided. Although debit and credit card use is increasing rapidly, many Chinese still prefer to use cash. This can be challenging, since the largest banknote in circulation is the 100-yuan note. The video shows the main protagonist as he tries to purchase a house and make other transactions and concludes by saying how easy it is to send someone money, do shopping or save money with the Spellthread+ App.

Another video, on Youtube, has a human narrator, a Moxian Product Specialist, who begins by saying that the ‘Moxian App integrates social media, loyalty rewards and games into a single platform’ and that ‘Moxian is designed to bring fun, convenience and benefits to people’. The Product Specialist has ‘a friend named Peter, a loyal user of Moxian, who shares nice pictures, fine foods and beautiful scenery in “Moments” anytime, anywhere.’ They became friends by meeting in one of the “Interest Groups” that can be created on the Moxian platform. The Product Specialist asks and answers, “Want to find the best French restaurant downtown? A fashionable dress? A nice place to spend your holiday? How about great deals from nearby stores? Maybe you want to meet someone special? No problem! Moxian is a magical world where you can find anything you’re looking for. “

For more information, visit the company’s website at

Posted in Moxian Inc. MOXC | Leave a comment

Torchlight Energy Resources, Inc. (TRCH) Well-Equipped To Profit amid Cheaper Oil with Premium Acreage Metrics in Texas and Kansas

In a tight oil market where the WTI price recently dipped below $30 a barrel again on the NYMEX, ranging down to around $26 a barrel in January (making it about half as expensive as milk on the Chicago futures market), only the best of the best can survive and thrive. Investors looking for E&P companies to add to their portfolios will want to focus on players that have a good mix of low lifting (production) costs, a solid footprint in established domestic plays with low jurisdictional risk and a balance sheet that is relatively clear of debt overhang.

One such company is Plano, Texas-based Torchlight Energy Resources (NASDAQ: TRCH), which, in this regard, made huge strides last year, achieving a total elimination of senior debt, divestment of non-core assets, and a successful reduction of overall lifting costs to under $15 a barrel. At the same time, the company has honed its primary focus and has set its sights on the potential billion-barrel Orogrande Basin discovery ( (WolfPenn) in West Texas, where it owns a 47.5 percent working interest on 168,000 acres alongside Founders Oil and Gas, LLC. Torchlight drilled the Rich A-11 well (6,091 feet) on the Orogrande Project in March last year and subsequently executed a $50 million JV farm-out agreement with Midland, Texas-based Founders Oil and Gas, who initiated frac work on the well in November (

Torchlight’s five-year Orogrande lease (which offers exceptional five-year renewal terms) covers the majority of the Orogrande Basin, and the approximately 1,400 feet of pay being targeted here (at a highly economical depth of 4,000 to 6,100 feet) was originated by famed Permian Basin geologist Rich Masterson. Masterson, a recipient of the 2014 Hearst Energy Award for Technology, is the guy who originated the famous Wolfbone play in the Delaware Basin using a combination of old school mud log perusal, sample analysis, and pure experience-based instinct. The Wolfcamp and Bone Spring shales, readily characterized by high oil content and liquids-rich natural gas, are a key feature of the multi-horizon Delaware Basin, which is the foundation for horizontal development in the Greater Permian. The Orogrande formed at the same time as the Delaware and Midland basins, and the company expects a nice 80/20 mix of oil and high BTU gas from the analogous siltstone present at Orogrande.

The core siltstone target is a 700-foot interval of clean/contiguous pay that will be digested in two sections, with the lower section receiving the initial effort’s attention, and being used to establish production potential, as well as behavioral characteristics. A full suite of logs on the Rich A-11 were analyzed by Haliburton (NYSE: HAL) and found to be very promising, with superb shows in a variety of formations and good overall permeability. Moreover, while around 100 units of background gas were anticipated during drilling, Torchlight encountered as much as ten times that amount and core results showed good pay in the analyzed zones, with over 2,000 pounds of virgin pressure. There is a lot to be excited about here for Torchlight and its investors, as the estimated ultimate recovery (EUR) potential based on analogous Midland Basin EURs is in the neighborhood of four to six million barrels per section, with as many as eighteen horizontals per section.

Now, Torchlight isn’t just a one-trick pony, mind you. The company has an impressive (yet streamlined) portfolio of operated and non-operated positions under its belt, including the Marcelina Creek Project in South Texas, with its prime access to the Austin Chalk, Buda, and Eagle Ford formations. Marcelina is surrounded on all four sides by leading Eagle Ford producers; there are as many as seven horizontal drilling locations for all of the pay zones on the lease, and the lease actually offsets an excellent Buda field drilled by none other than Exxon (NYSE: XOM). The company has three producing wells with a combined BOPD of around 60 bbls already – 100 percent of CAPEX is paid by two of the company’s non-op industry partners, and Torchlight is preparing to drill a second Austin Chalk well sometime here in Q1.

On February 1, Torchlight announced a successful re-entry to one of its over 20 drilling locations on the Marcelina Project’s lease, where the company owns 75 percent WI on a 1,080-acre block, as well as a 50 percent WI on a smaller 280 acre block. The company’s Johnson #4 was drilled out laterally into the Austin Chalk about 2,500 feet and has subsequently shown increasing fluid and gas entry (, with 540 bbls over three eight-hour days, and liquids-rich gas up to 80 percent oil cut. With the shut in tubing holding steady around 470 PSI and good swab results thus far, Torchlight is quite excited about forthcoming initial production figures from this recompleted well that was previously running only 10 BOPD. Investors should keep an ear to the ground in coming weeks for an update from the company on the Johnson #4 and take note of how Torchlight has unlocked serious potential here at Marcelina from what was a marginally producing well – a feat which indicates similar potential across the company’s promising asset base and also reinforces the validity of its exploitation thesis that is being applied selectively thereto.

Torchlight also has a JV with Ring Energy (NYSE MKT: REI) to do E&P in the massive Hugoton Field area of Kansas, where the company is matching Ring Energy’s lease cost by drilling wells, and stands to end up owning a 50 percent interest across the entire 17,000-plus acre block. With numerous shallow pay zones around 5,200 feet, ranging from the Chase Formation through to Mississippian Age carbonates, cheap vertical well completion totals of around $550,000, and anticipated initial production levels in the neighborhood of 100 to 300 BOPD – Torchlight has every reason to be eager about seeing new well starts here in Q2 targeting the Morrow Formation.

In addition, Torchlight has some choice assets at the Cimarron Project outside Oklahoma City in the Edmonds Field that it is currently selling, and has already announced the first of six intended sales. This first sale, to Husky Ventures, will reportedly bring in over $1.4 million net from a $4.6 million price tag, and has already produced a partial cash closing for the company.

These are exciting times for this lean and mean E&P junior, which is focused squarely on profitable domestic drilling, as well as working interest programs with a near-term payback window.

For more information, visit

Posted in Small Cap News | Leave a comment

Pudo, Inc. (PDPTF) Offers a Creative Solution to End the Hassles of Package Pickup and Delivery

Named one of the most innovative public technology companies by the Canadian Innovation Exchange in 2015, Ontario-based Pudo, Inc. (OTCQB: PDPTF) represents one of the latest “why didn’t I think of that” ideas. The company’s idea, now available across Canada and the U.S., is a customizable pick-up and drop-off service, allowing anyone to specify one of thousands of third-party locations where packages can be picked up or dropped off for delivery.

What that means for the consumer is that they don’t have to worry about not being at home for a delivery or trying to get to the post office or a distant shipping center before it closes. Instead, they can have the package delivered to what the company calls PUDO Points, which can be a nearby convenience or grocery store or even a gas station, any one of thousands of places that are part of the company’s growing partner network. The consumer is notified by email when the item arrives, and then simply picks the package up there, at locations that are convenient to reach and open long hours, 7-days-a-week. Additionally, anyone can also ship packages from the same locations, at times when other options are closed. For the consumer the only requirement is that they become a free PUDO member.

It’s a service that is obviously great for the consumer, but it’s also valuable to the partner-store because of the increased traffic it draws. As the PUDO user community grows, greater traffic will be generated. PUDO supplies partners with technology to coordinate shipments, and provides courier arrangements to attract foot traffic and PUDO members for domestic and international shipping. PUDO members receive discounts on their shipping and stores earn revenue. In addition, PUDO gives training to ensure consistent service standards are met.

PUDO already has affiliate agreements with some of North America’s best-known retailers, including Amazon (NASDAQ: AMZN), eBay (NASDAQ: EBAY), Hudson’s Bay (OTC: HBAYF), and Walmart (NYSE: WMT), and it has recently entered into a marketing agreement with Innovative Marketing to provide PUDO with advertising and investor relations services. The company is now planning to raise up to $1.375 million through a non-brokered private placement, to “pursue the expansion of their location network in Canada and the United States, pursue strategic partners and retailers, and for general working capital”.

For more information visit: or

Posted in Small Cap News | Leave a comment

Content Checked Holdings, Inc. (CNCK): Healthy Living Should Start with Our Children

Building good habits is the key for living a longer and healthier life. Developing these behaviors during adolescence can be an added benefit, as habits will develop and grow into a healthier adulthood. As individuals, our behavior is simply a stream of habits, which can be good or bad for our physical, mental, and emotional health. Eating a balanced diet, exercising regularly, and constantly learning and growing mentally are the foundation for a healthy lifestyle, and should be practiced regularly and early on in life.

If you’re not sure where to begin when it comes to building better dietary habits, begin with grocery shopping. Shopping for ingredients for an entire week’s meals can be a daunting task, even for the seasoned soccer mom with years of PTA experience. One company’s mission is to make this process easier while educating consumers throughout the process – Content Checked Holdings, Inc. (OTCQB: CNCK). CNCK’s suite of mobile apps (ContentChecked, SugarChecked, and MigraineChecked) allows shoppers to set their dietary restrictions, and scan the barcodes of food items to quickly and easily find out if that product is suitable for their dietary needs. If the product is not suitable for the user, then the apps will offer similar alternatives that do meet their dietary needs. Recipes that are catered to each user’s specific dietary restrictions are also available in the apps.

In a recent article on the Jakarta Post website (, journalist Stuti Agrawal emphasized the importance of a healthy lifestyle for teenagers: “Firstly, in the early stages of adolescence, the body requires a lot of calories. In general, teenage boys need to consume 2,800 calories each day and teenage girls need to consume 2,200 calories per day. An excessive intake of calories can result in serious health problems such as obesity, type 2 diabetes and heart disease. Obesity is most common among teens today because of the wrong choices they make in their diet. Today, junk food such as pizza, burgers, fries and soda, which have little nutritional value and contain excessive fat, sugar, salt and calories, are the major portion of teenagers’ diets.”

A healthy exercise routine is essential for maintaining proper body weight. If you stay active by doing simple everyday tasks, such as walking your dog, taking your kids to the park, making smart decisions at the grocery store, and cooking balanced meals, you will be much more likely to attain and maintain a healthy body without having to spend two or three hours at the gym every single day.

Lastly, exercising and advancing your mind is an imperative component in maintaining and improving your overall quality of life. Effectuate a healthy lifestyle – it’s never too early or too late to start!

For more information, visit

Posted in ContentChecked Holdings Inc. CNCK | Leave a comment

International Stem Cell Corporation (ISCO) Continues Upward Climb toward Changing the Face of Regenerative Medicine

A California-based biotechnology company, International Stem Cell Corporation (OTCQB: ISCO) focuses its energies on developing restorative medicine using stem cell technology. Its innovative parthenogenesis technology uses human stem cells derived from unfertilized oocytes (eggs), which helps the company avoid any ethical issues involving the destruction of viable human embryos. ISCO also produces and markets cells and growth media for therapeutic research worldwide through its subsidiary, Lifeline Cell Technology. For even more revenue, the company’s other subsidiary, Lifeline Skin Care, markets and sells a skin care line that promises rejuvenation and beauty.

In December, Lifeline Skin Care launched its Molecular Renewal Serum™, just in time for the holidays. This product contains an impressive nano-compound that works with skin to replenish elasticity and smoothness. During testing, the serum showed improvement in skin’s resilience and a decrease in roughness without any negative side effects. The serum also stimulates collagen production, which lends strength to skin by regrowing dead skin cells.

That same month, ISCO announced that it had entered a master clinical research agreement with Florey Institute of Neuroscience and Mental Health, one of the world’s leading brain research centers. The agreement cleared the way for scientists to conduct a Phase I/IIa clinical trial studying the effects of human parthenogenetic stem cells in people with Parkinson’s disease. Patients are to be enrolled during the first quarter of 2016.

ISCO’s groundbreaking stem cells are created by stimulating oocytes into dividing themselves into histocompatible cells. The company strives to create immune matching cells, so that people do not reject the treatment. So far, ISCO scientists have developed the first line of stem cells that can be used as therapeutic cells for millions of people with minimal rejection. The company also aligns itself with the UniStemCell Bank, the first collection of non-embryonic stem cells, in the hopes of increasing widespread use and scientific breakthroughs.

With the steady financial growth of ISCO and its subsidiaries, the company hopes to continue making great strides in regenerative techniques for eye, liver, and nervous system diseases.

For more information, visit

Posted in International Stem Cell Corp. ISCO | Leave a comment

Pulmatrix, Inc. (PULM) COPD Treatment Candidate Reinforces Sweeping Potential of Company’s Proprietary iSPERSE Inhaled Dry Powder Tech

According to the latest official data published by the American Lung Association, the extremely debilitating and incurable progressive lung disease known as chronic obstructive pulmonary disorder (COPD) currently impacts as many as 24 million Americans ( The WHO estimates that by 2030, COPD will be the third leading cause of death and has ruled the disease a global epidemic. This statistic is, unfortunately, already true here in the U.S., where we have around 13.6 million cases currently diagnosed. COPD is actually a catch-all term for a host of lung diseases and associated ailments, like chronic bronchitis (increased mucus and inflammation) and emphysema (progressive alveoli damage), as well as refractory asthma and bronchiectasis (scarring/enlargement in damaged airways), to name but a few.

Naturally, because there is no cure, there is a sizable and growing treatment market for COPD, and one whose growth is being spurred on globally by an increasingly elderly population. In fact, the U.S. Department of Health and Human Services estimates that the older population in America alone will increase by some 120 percent through 2060. Compared to 2013’s ratio of about 14 percent (one out of every seven citizens), the number of COPD patients will more than double over this interval, to a total somewhere around 100 million.

Given that women are at particular mortality risk ( due to a sizable uptick in female smokers starting around the late 1960’s, and that women have an inordinate susceptibility to COPD when compared to men, due to their smaller-on-average lungs and the fact that estrogen plays a key role in the worsening of the disease, COPD-related death is notably higher among women. The roughly 7 million women in the U.S. who are currently diagnosed with COPD are not only severely debilitated by an inability to breathe properly, they face a higher risk of having their lives cut short by this disease, which was historically considered to be more of a man’s disease. A four-fold increase in fatalities among women over the past three decades has thrown a bright spotlight on how misdiagnosed the disease is among women, but the problem still persists, meaning that the emergence of new and easy to use treatments are highly sought after by this eager demographic.

Thankfully a number of treatments have already emerged to help prevent complications, such as airflow obstruction and bronchospasm, in COPD patients, including GlaxoSmithKline’s (NYSE: GSK) Anoro Ellipta, a so-called LAMA/LABA (long-acting muscarinic antagonist/beta agonist) once-daily, which was designed to also help maintain profitability for GSK as its mainstay Seretide/Advair (salmeterol and fluticasone) product is opened up to generic competition. One of the big hurdles generics have faced, however, is the difficulty in getting the delivery mechanism, an inhaler, properly designed – a factor which has led to much slower than expected onset of generic competition for GSK. Novartis (NYSE: NVS) also made progress in this same area last year with solid results in a pivotal U.S. Phase III clinical trial of twice-daily QVA149 (indacaterol/glycopyrronium bromide) and NVA237 (glycopyrronium bromide), as well as a more recent expansion of its relationship with Qualcomm’s (NASDAQ: QCOM) Qualcomm Life subsidiary, aimed at powering Novartis’ next-gen Breezhaler delivery system for its COPD portfolio (Onbrez, Seebri and Ultibro).

According to leading business intelligence provider GBI Research, the global COPD market is estimated to be worth approximately $11.3 billion ( and is on-track to grow by around 38 percent over the next few years, reaching upwards of $15.6 billion on the strength of LABA/LAMA bronchodilators by 2019. One of the extremely attractive contenders amid this multibillion dollar market is clinical stage biopharma Pulmatrix (NASDAQ: PULM), which has already completed a Phase 1b in patients with moderate to severe COPD using its branded generic bronchodilator PUR0200, for which there is currently no generic competition. PUR0200 has demonstrated efficacy at a much smaller dose than the reference target and the Phase 1b also clearly documented the efficiency of what is the company’s first small molecule formulation using its iSPERSE inhaled dry powder technology (, via comparison with traditional lactose blend formulations.

This is great news for the company and indicates to investors the potential for PULM’s technology, considering how iSPERSE now very strikingly appears to have the potential to enable delivery of entirely new classes of compounds directly to the lungs, something not possible with traditional lactose delivery technologies. An R&D partnership with global pharmaceutical developer and generics juggernaut Mylan (NASDAQ: MYL) in Europe spells big things for Pulmatrix’s PUR0200, and the drug could become the first branded generic for what is a roughly $5 billion segment of the larger global COPD market.

Moreover, the company has a robust IP position with some 37 issued patents worldwide covering its core dry powder technology, iSPERSE (inhaled small particles easily respirable and emitted), a proprietary platform solution that hurdles many of the lagging formulation problems facing the industry today that are typically seen with other lactose blend and metered dose inhaler technologies. Because iSPERSE particles don’t require a carrier such as lactose and can be engineered to carry anywhere from less than one percent to more than eighty percent of an active pharmaceutical ingredient (API), Pulmatrix has an extremely versatile delivery technology on its hands that is suitable for a wide range of drug loading roles – from small molecules, to peptides and proteins, or even antibodies. Pulmatrix could go toe to toe and even surpass sector heavy-hitters such as AstraZeneca (NYSE: AZN) and Bayer (OTC: BAYRY) in certain areas of the COPD market with this technology, and the company’s team of engineers have a deep understanding of the iSPERSE platform that spans the implantation gamut, from feasibility to clinical manufacturing, something which makes PULM a force to be reckoned with when it comes to novel inhalation products.

Indeed, such formulation prowess is just the tip of the iceberg for PULM’s iSPERSE platform, as the technology features numerous other characteristics that set it apart from competitors when it comes to significantly improving the treatment of a whole host of pulmonary diseases, as well as opening the door to important new inhalation products with important characteristics such as reproducible, one-step, scalable manufacturing – using a unique spray drying process that offers high quality, consistent yields of end product, which are completely independent of specific API physical chemistries. When you stack this advantage up against the optimum dispersibility across a range of flow rates, noting that iSPERSE formulations nevertheless feature consistent emitted dose and particle sizes, one can see that you get an easy to churn out, reliable dosing solution, a solution which is right for all patient populations and which uniquely addresses the problem of delivery variance from patient to patient.

Additionally, because iSPERSE allows for the delivery of macromolecules and biologics such as antibodies, peptides and nucleic acids across such wide range of drug loads – and because the technology enables the creation of dual and even triple homogenous combinations of multiple drugs – this platform technology is an ideal vehicle for Pulmatrix’s future candidates, and the Pulmatrix pipeline ( already offers some other exciting candidates alongside its lead, such as PUR1900 and PUR1500, designed (respectively) to treat the pulmonary fungal infections that affect half or more of all cystic fibrosis patients, as well as the loss of lung tissue oxygen transport capability common in idiopathic pulmonary fibrosis.

PUR1900 is particularly interesting, as it has been shown to be both active and potent in animal models (, achieving high lung concentrations and low systemic exposure, and because it would be the first ever inhalable anti-fungal for cystic fibrosis. Because PUR1900 directly targets aspergillus infection – which is typical of several other conditions such as suppressed immune function among leukemia-related chemotherapy or tuberculosis, and is seen in non-invasive nose, ear and eye infections – there are tantalizing upper limits when it comes to PUR1900’s broader applicability.

With a $1.7 million NIH research grant under its belt to work on an inhaled anti-fibrotic with Celdara, Inc. (, as well as a strong cash position of some $22 million ( that should see development efforts at the company through to the middle of next year, Pulmatrix is in an enviable position, with a robust pipeline of candidates, the capital muscle, and the bedrock tech to back up its aspirations. The company has a truly impressive drug delivery/manufacturing technology in iSPERSE that should continue to produce upside moving forward and investors will want to keep a close eye on PULM for news regarding further PUR0200 developments that are on the immediate horizon.

Take a closer look, visit

Posted in Small Cap News | Leave a comment